En Es
Productos
Covid-19
Compañías
Segunda mano
Noticias
Eventos
Acerca de nosotros:       ¡Únase ahora!
Categorías

Ver productos por categoría

Cuidados intensivos

Medicina de emergencia

Cuidados intensivos

Cuidado respiratorio

Sistemas de Anestesiología

Cuidados domiciliarios

Rehabilitación

Otro

Infraestructura hospitalaria

Equipamiento TI

Sistemas de Transporte

Gestión de residuos

Otro

Imágenes medicas

Tomografía computarizada

Radiografía Digital

Sistemas de gestión de imágenes

Radiología intervencionista

Imágenes por resonancia magnética

Mamografía

PACS / RIS

Tomografía de emisión de positrones

Seguridad de las radiaciones

Radiografía

Tomografía computarizada de emisión de fotón único

Ultrasonido

Otro

Atención al paciente

Cuidado bariátrico

Camas

Equipos de examen

Otro

Cirugía

Endoscopia

Laparoscopia

Cirugía laser

Equipamiento de quirófano

Esterilización

Implantes quirúrgicos

Instrumentos quirúrgicos

Gestión de residuos

Otro

Expo: Laboratorio clínico

Analizadores de Sangre y Gas

Contadores de Células

Centrífugas

Analizador de Química Clínica

Analizadores de Coagulación

Laboratorio General

Analizadores de Hematología

Sistemas de Inmunoensayo

Cristalería de Laboratorio

Lector de Microplacas

Microscopios

Pipetas

Pruebas Rápidas

Kits para Análisis Listos para Usar

Analizador de Orina

Pruebas Punto de Atención

Ver productos por categoría

Cerrar

Pacific Edge

Pacific Edge

Pacific Edge Limited is a global cancer diagnostics company focused on the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The company provides its suite of Cxbladder tests globally through its wholly owne ...
Productos Resumen
Close

Sobre Pacific Edge

Pacific Edge Limited is a global cancer diagnostics company focused on the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Actualizado

Bladder Cancer Test
Cxbladder Monitor

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. It accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.
Mas detalles

Bladder Cancer Test
Cxbladder Resolve

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. When used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), it assists clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritized for further investigation in high throughput settings.
Mas detalles

Bladder Cancer Test
Cxbladder Triage

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. It is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.
Mas detalles

Laboratorio clínico

Bladder Cancer Test
Cxbladder Monitor

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. It accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.
Mas detalles

Bladder Cancer Test
Cxbladder Resolve

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. When used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), it assists clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritized for further investigation in high throughput settings.
Mas detalles

Bladder Cancer Test
Cxbladder Triage

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. It is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.
Mas detalles

Bladder Cancer Test
Cxbladder Detect

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. It provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.
Mas detalles
Derecho de autor © 2000-2026 TradeMed.com. Todos los derechos reservados. | Términos y condiciones